GSGovindaswamy Shanmugam

Govindaswamy Shanmugam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Govindaswamy Shanmugam has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Gs Selvam

    Department of Biochemistry, Centre for Advanced Studies in Functional Genomics, School of Biological Sciences, Madurai Kamaraj University, Madurai, India

    1 shared publication
  • Muthusamy Viswanathan

    Cancer Biology Division, Centre of Excellence in Genomic Studies, School of Biological Sciences, Madurai Kamaraj University, Madurai, India

    1 shared publication
  • Nobuo Tsuchida

    Department of Molecular and Cellular Oncology and Microbiology, Tokyo Medical and Dental University, Tokyo, Japan

    1 shared publication
  • Pr Solomon

    Department of Biochemistry, Centre for Advanced Studies in Functional Genomics, School of Biological Sciences, Madurai Kamaraj University, Madurai, India

    1 shared publication

Latest Publications

  • Polymorphism in ADH and MTHFR genes in oral squamous cell carcinoma of Indians

    by Pr Solomon, Gs Selvam, G Shanmugam

    Objectives:  Alcohol consumption is known to increase the risk for several cellular disorders like oral cancer. The risk may be reinforced by polymorphism in genes like alcohol dehydrogenase. Therefore, this study is designed to asses the polymorphic status in ADH1B (formerly ADH2), ADH1C (formerly ADH3) and MTHFR genes in order to correlate the susceptibility to oral squamous cell carcinoma (OSCC).Subjects and methods:  DNA from 126 OSCC samples were amplified using primers for ADH1B, ADH1C and MTHFR genes. The amplicons were analyzed for ADH1B*1, ADH1C*2 and MTHFR C677T allelic polymorphism by restriction digestion using appropriate enzymes.Results:  ADH1B*1/*1 genotype in cancer patients who were heavy drinkers showed a negligible risk association with an odds ratio of 1.62; 95% CI = 1.08–2.14. In OSCC patients, ADH1C*2/*2 genotypes showed a relatively higher risk (odds ratio 2.65; 95% CI = 1.78–3.53) in heavy drinkers and a less significant risk (1.6; 95% CI = 1.15–2.03) in moderate drinkers and negligible risk in light drinkers (1.23; 95% CI = 0.77–1.63). In contrast, MTHFR 677TT genotype showed a high risk association for OSCC in heavy drinkers (odds ratio 3.0; 95% CI = 2.02–4.0). Interestingly, the combination of ADH1B*1/*1/ MTHFR 677TT genotypes in alcoholic cancer patients showed a high risk (odds ratio 4.16; 95% CI = 2.78–5.53). A similar risk (odds ratio 4.16; 95% CI = 1.18–5.53) was shown by ADH1B*1/*2/*2/*2MTHFR 677TT genotype combination. The ADH1C*2/*2 /MTHFR 677TT genotype combination showed the maximum risk (odds ratio 20; 95% CI = 13.45–26.64) in the heavy drinker group. This combination showed a high risk in moderate drinkers (odds ratio 5.88; 95% CI = 4.24–7.50) and relatively lower risk in light drinkers (odds ratio 2.77; 95% CI = 1.74–3.68).Conclusions:  The ADH1C*2/*2/MTHFR 677TT genotype combination appears to be more susceptible for OSCC, since it showed a 20‐fold increase in risk in heavy drinkers and a 5.9‐ and 2.8‐fold increase in risk respectively in moderate drinkers and light drinkers. This study suggests the association of ADH1C*2/*2/MTHFR 677TT genotype combination as a risk factor for OSCC in alcoholics.


  • Open Access

    Promoter hypermethylation profile of tumor‐associated genes p16, p15, hMLH1, MGMT and E‐cadherin in oral squamous cell carcinoma

    by Muthusamy Viswanathan, Nobuo Tsuchida, Govindaswamy Shanmugam

    Aberrant promoter hypermethylation of tumor‐associated genes leading to their inactivation is a common event in many cancer types. Using a sensitive restriction‐multiplex PCR method, we studied the promoter hypermethylation profile of the p16, p15, hMLH1, MGMT and E‐cad genes in oral squamous cell carcinoma (OSCC) of Indians. We analyzed a total of 51 samples for the p15 tumor‐suppressor gene and 99 samples for each of the remaining genes. Our studies indicate an incidence of promoter hypermethylation of 23% each for p16 and p15, 8% for hMLH1, 41% for MGMT and 35% for E‐cad. We observed aberrant hypermethylation of the promoter region of at least 1 of these genes in 74.5% of cases (n = 51) for which all the 5 genes were studied. Abnormal methylation was detected in tumors irrespective of stage and location in the oral cavity, whereas no abnormal methylation was detectable in normal oral squamous tissues obtained from 25 OSCC patients. Detection of aberrant hypermethylation patterns of cancer‐associated genes listed above is therefore suitable for diagnosis of OSCC in individuals at high risk for this disease.